查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2128957

罕見腎臟病市場：按適應症、分子類型、生物製藥類型、給藥途徑、治療類型、國家和地區分類－行業分析、市場規模、市場佔有率和預測（2026-2033 年）

Rare Kidney Diseases Market, By Disease Indication, By Molecule Type, By Biologics Type, By Route of Administration, By Therapy Type, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 222 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2025 年，罕見腎臟病市場價值將達到 32.906 億美元，並將在 2026 年至 2033 年期間以 11.6% 的複合年成長率成長。

罕見腎臟病市場涵蓋用於治療罕見腎臟疾病的藥物和產品，例如補體介導性疾病、遺傳性溶小體貯積症、免疫介導的腎絲球病變以及伴隨蛋白尿的疾病。治療基礎包括生物製藥、口服小分子藥物、酵素替代療法、免疫調節療法和標靶訊號通路療法，其目標是控制蛋白尿並維持腎功能。市場動態正從對症治療轉向基於機制的干預，針對補體、內皮素、APRIL 和免疫路徑。 FDA 於 2025 年批准 C3G 和 IgA 腎病症候群的藥物，以及多國臨床試驗的擴展，都支持了這一轉變。因此，差異化重點在於生物標記的選擇、對腎功能的長期益處以及劑量。

罕見腎臟病市場－市場動態

基於作用機制的法規核准正在加速治療方法的廣泛應用。

2025年的監管進展透過闡明治療應用的生物學證據，提高了人們對某些罕見腎臟疾病的關注。 2025年3月20日，FDA核准iptacopan治療C3G；2025年4月2日，FDA核准Atrasentan用於治療IgA腎臟病。這些監管決定是基於一項涉及74名成年患者的隨機試驗結果，該試驗顯示，在安慰劑校正後的6個月評估中，蛋白尿減少了35%。 ALIGN計畫在18個國家的99個研究中心進行了Atrasentan臨床試驗，利用了來自270名患者36週的數據。因此，2025年的監管批准透過標靶治療得到了地域分佈廣泛的研究中蛋白尿減少的支持。

罕見腎臟病市場－市場區隔分析：

全球罕見腎臟病市場按適應症、分子類型、生物製藥類型、給藥途徑、治療類型和地區進行細分。

從疾病適應症來看，疾病適應症是治療策略的關鍵區分因素，C3G、非典型溶血性尿毒症候群（aHUS）、法布瑞氏症、IgA腎病變症候群、局部節段性腎絲球硬化症（FSGS）、狼瘡性腎炎和膜性腎臟病變各自遵循不同的治療路徑。 IgA腎病症候群在已核准的標靶治療方面適應症最為廣泛，而首個獲得FDA認證核可藥將於2025年上市。法布瑞氏症以酵素替代療法和Chaperone療法為特徵，aHUS主要透過補體抑制發揮作用，而FSGS則採用路徑特異性療法。由於狼瘡性腎炎和膜性腎臟病變具有免疫異質性，後者更適合使用分化型生技藥品和小分子藥物。隨著市場結構的細分，能夠維持腎功能、控制蛋白尿並開發特異性疾病的作用機制的公司將在所有這些適應症中獲得更強的競爭優勢。

從分子類型來看，市場可分為兩大類：生物製藥和小分子藥物，二者的研發特徵各不相同。生物製藥適用於可透過選擇性免疫調節或補體調節來靶向疾病生物學機制的情況。 2025年，大塚製藥在一項針對IgA腎臟病的臨床試驗中證實，與安慰劑相比，西貝普利單抗注射液在9個月時可使蛋白尿減少51.2%。另一方面，小分子化合物具有口服給藥、劑量柔軟性、易於製劑等優勢，例如伊普他可泮和Atrasentan。因此，競爭優勢不僅取決於分子類型，還取決於選擇性、便利性、安全性監測以及維持腎功能的有效性。

罕見腎臟病市場—區域洞察

北美地區憑藉其活躍的法規環境、完善的腎臟病生態系統和先進的研發能力，成為罕見腎臟疾病領域的重要區域。 2025年，美國FDA核准了兩項重要的藥物：3月20日核准用於治療C3G的Atrasentan ，4月2日核准用於治療IgA腎臟病的Atrasentan的ALIGN試驗是一項多國參與的臨床試驗，在18個國家的99個研究中心開展，共納入270名患者，隨訪36週，凸顯了該地區與國際臨床研發網路的緊密聯繫。此外，美國的生態系統也促進了補體抑制劑、生物製藥和口服標靶治療的商業化。因此，北美地區在罕見腎臟疾病的監管開拓、臨床證據的累積和產品上市方面，仍保持著舉足輕重的地位。

歐洲是罕見腎臟病治療的關鍵樞紐，這得益於其協調的監管流程、完善的腎臟病學生態系統以及臨床證據轉化為產品准入的趨勢日益增強。 2025年2月，歐洲藥品管理局（EMA）人用藥品委員會（CHMP）基於一項III期臨床試驗的證據，批准了用於治療C3G的iptacopan，該試驗證實該藥物可使蛋白尿減少高達35.1%，並穩定eGFR。 2025年4月，歐盟委員會將用於治療IgA腎臟病的sparsentan的有條件批准轉為在歐盟成員國、冰島、列支敦士登和挪威的正式上市許可。這些監管決定凸顯了基於機制的治療方法在歐洲腎臟病治療中日益成長的重要性。因此，歐洲為罕見腎臟病治療藥物的生產商提供了完善的監管途徑和處方醫生網路。

目錄

第1章：罕見腎臟病市場概覽

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：罕見腎臟病市場的主要趨勢

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 未來市場趨勢

第4章：罕見腎臟病產業分析

  • PEST分析
  • 波特五力分析
  • 市場成長前景展望圖
  • 管理體制分析

第5章：罕見腎臟病市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：罕見腎臟病市場趨勢

  • 罕見腎臟病市場佔有率分析（2025 年）
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章：罕見腎臟病市場：依適應症分類

  • 概述
    • 基於細分市場的市場佔有率分析：按適用疾病分類
    • C3腎絲球腎炎（C3GN）
    • 非典型溶血性尿毒症候群（aHUS）
    • 法布瑞氏症
    • 免疫球蛋白A（IgA）腎臟病
    • 局部節段性腎絲球硬化症（FSGS）
    • 狼瘡性腎炎
    • 膜性腎臟病
    • 其他

第8章：罕見腎臟病市場：依分子類型分類

  • 概述
    • 基於細分市場的市場佔有率分析：按分子類型
    • 生物製劑
    • 低分子化合物

第9章：罕見腎臟病市場：依生物製藥類型分類

  • 概述
    • 細分市場佔有率分析：依生物製藥類型分類
    • 蛋白質
    • 單株抗體

第10章：罕見腎臟病市場：依給藥途徑分類

  • 概述
    • 按給藥途徑分類的市佔率分析
    • 靜脈
    • 口服
    • 其他

第11章：罕見腎臟病市場：依治療類型分類

  • 概述
    • 基於細分市場的市場佔有率分析：按治療類型
    • 聯合治療
    • 單藥治療

第12章 罕見腎臟病市場：依地區分類

  • 介紹
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 主要製造商：歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 丹麥
    • 其他歐洲國家
  • 亞太地區
    • 概述
    • 主要製造商：亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 台灣
    • 越南
    • 其他亞太國家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家
  • 中東和非洲
    • 概述
    • 主要生產商：中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 伊朗
    • 卡達
    • 其他中東和非洲國家

第13章：主要供應商分析：罕見腎臟病產業

  • 競爭基準
    • 競爭對手儀錶板
    • 競爭定位
  • 公司簡介
    • Merck & Co., Inc.
    • Sanofi SA
    • AstraZeneca plc/AstraZeneca Rare Disease
    • Novartis AG
    • Otsuka Pharmaceutical Co., Ltd.
    • Amgen Inc.
    • Protalix Biotherapeutics Inc.
    • Recordati SpA
    • Amicus Therapeutics, Inc.
    • Travere Therapeutics, Inc.
    • FibroGen, Inc.
    • Akebia Therapeutics, Inc.
    • Aurinia Pharmaceuticals Inc.
    • Asahi Kasei Corporation（Calliditas Therapeutics）
    • Apellis Pharmaceuticals, Inc.
    • Vertex Pharmaceuticals Incorporated
    • Vera Therapeutics, Inc.
    • Omeros Corporation
    • Alnylam Pharmaceuticals, Inc.
    • Others

第14章：AnalystView 的全景視圖

簡介目錄
Product Code: ANV7326

Rare Kidney Diseases Market size was valued at US$ 3,290.6 Million in 2025, expanding at a CAGR of 11.6% from 2026 to 2033.

The rare kidney diseases market includes pharmaceuticals and products treating rare kidney conditions, such as complement mediated diseases, hereditary lysosomal disorders, immune-mediated glomerulopathies, and proteinuric conditions. Their therapeutic foundations include biologics, oral small molecules, enzyme replacement, immunomodulation, and pathway-targeted therapy; proteinuria control and renal function maintenance are treatment goals. A market dynamic is unfolding from symptomatic treatment to mechanism guided intervention, including, complement, endothelin, APRIL, and immune pathways. This shift was confirmed by FDA approvals in C3G and IgA nephropathy in 2025, which were also substantiated by the expansion of multinational clinical trials; accordingly, differentiation is centered on the selection of biomarkers, long-term renal benefit, and dosing.

Rare Kidney Diseases Market- Market Dynamics

Mechanism-Specific Regulatory Validation Is Broadening Treatment Adoption

Regulatory developments in 2025 increased the focus on selective rare kidney disorders through biological rationalization to therapeutic applications. FDA approval for iptacopan was granted for C3G on March 20, 2025, whereas atrasentan was approved for IgA nephropathy on April 2, 2025. This regulatory decision was based on the results of a randomized trial comprising 74 adults and a 35% reduction in proteinuria by the six-month assessment adjusted for placebo. The clinical trials for atrasentan under ALIGN included 99 trial sites in 18 countries, utilizing data from 270 patients over 36 weeks. Thus, regulatory approvals in 2025 made the treatment options available for patients suffering from rare kidney disorders more effective through targeted therapies substantiated by the reduction of proteinuria in geographically varying studies.

Rare Kidney Diseases Market- Segmentation Analysis:

The Global Rare Kidney Diseases Market is segmented on the basis of Disease Indication, Molecule Type, Biologics Type, Route of Administration, Therapy Type, and Region.

By disease indication, the disease indication is a determinant for therapeutic differentiation, with C3G, aHUS, Fabry disease, IgA nephropathy, FSGS, lupus nephritis, and membranous nephropathy being separate pathways. The most diverse indication in terms of approved targeted therapies is IgA nephropathy, and C3G had its first FDA-approved drug in 2025. Fabry disease is characterized by enzyme replacement and chaperone-based approaches; aHUS are complemented inhibition-driven, and FSGS is pathway-directed. The immunological heterogeneity of lupus nephritis and membranous nephropathy makes the latter more favorable for differentiated biologics and small molecules. The fragmentation of the landscape means that companies that can preserve renal function, control proteinuria, and develop disease-specific mechanisms will gain stronger competitive positioning in all these indications.

By molecule type, the molecule type creates a split in the market between biologics and small molecules, which have different development features. Biologics are relevant in situations where the disease biology can be tackled by selective immune or complement modulation. In 2025, Otsuka showed a 51.2% proteinuria reduction in IgA nephropathy trials compared with placebo at nine months after sibeprenlimab injection. Small molecules, for their part, have advantages of oral delivery, dosing flexibility, and easier formulation as demonstrated by iptacopan and atrasentan. Thus, competitive positioning is driven not only by molecule type but rather by selectivity, convenience, safety monitoring, and effectiveness of renal preservation.

Rare Kidney Diseases Market- Geographical Insights

North America is an important region for rare kidney disorders due to the presence of an active regulatory environment, nephrology ecosystem, and advanced development capabilities. The U.S. achieved two significant FDA approvals in 2025: iptacopan for C3G on March 20 and atrasentan for IgA nephropathy on April 2. Despite the multinational nature of the ALIGN study conducted for atrasentan, which included 99 sites across 18 countries and 270 patients at week 36, its evidential base emphasizes the integration of the region into international clinical development networks. Moreover, the U.S. ecosystem facilitates the commercialization of complement inhibitors, biologic drugs, and oral targeted therapies. Thus, North America retains its status as the region with significant activities of regulatory first movers, the creation of clinical evidence, and the sequencing of product launches in rare renal disorders.

Europe has become an important hub for rare kidney medicines due to its coordinated regulatory processes, a nephrology ecosystem, and the growing translation of clinical evidence into product access. In February 2025, the CHMP of the EMA approved iptacopan for C3G based on Phase 3 evidence confirming a decrease in proteinuria of up to 35.1% and eGFR stabilization. In April 2025, the European Commission transformed the conditional authorization of sparsentan for IgA nephropathy into standard marketing authorization across EU member states, Iceland, Liechtenstein, and Norway. Thus, these regulatory decisions confirm the growing importance of mechanism-based approaches in European renal care. As a result, Europe offers a developed regulatory pathway and a prescriber network for manufacturers of rare kidney therapies.

Rare Kidney Diseases Market- Competitive Landscape:

Competition within the rare kidney disease market continues to evolve into the validation of disease mechanisms and clinical differentiation, in addition to portfolio diversity. Novartis strengthen its position with its drug iptacopan, as the treatment covered both C3G and IgA nephropathy, advancing their renal portfolio with 33 abstracts from their cardiovascular, renal, and metabolic portfolio at ASN Kidney Week 2025. Otsuka continued the development of sibeprenlimab through Phase 3 and reported a 51.2% placebo-adjusted reduction in proteinuria in nine months. Travere Therapeutics and CSL Vifor expanded sparsentan's geographical reach, leveraging its European standard authorization and indications for FSGS. Companies with differentiated mechanisms, regulatory expertise, biomarker-specific data, and a multi-disease approach are positioned to establish strong franchises in fragmented rare kidney markets.

Recent Developments:

In March 2025, Novartis' FDA approval of Fabhalta (iptacopan) for adult patients with C3G, targeting proteinuria reduction, marked the first FDA-approved treatment for the C3G indication. This approval significantly increased competition among drugs targeting the complement pathway and set a new benchmark in the treatment of C3G disease.

In November 2025, Otsuka Pharmaceutical's FDA approval of VOYXACT (sibeprenlimab) for the reduction of proteinuria in adults with primary IgA nephropathy who are at risk of progression introduced a new APRIL-targeting biologic and enhanced diversity in the treatment mechanisms of IgA nephropathy.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RARE KIDNEY DISEASES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Merck & Co., Inc.
  • Sanofi S.A.
  • AstraZeneca plc / AstraZeneca Rare Disease
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Amgen Inc.
  • Protalix Biotherapeutics Inc.
  • Recordati S.p.A.
  • Amicus Therapeutics, Inc.
  • Travere Therapeutics, Inc.
  • FibroGen, Inc.
  • Akebia Therapeutics, Inc.
  • Aurinia Pharmaceuticals Inc.
  • Asahi Kasei Corporation (Calliditas Therapeutics)
  • Apellis Pharmaceuticals, Inc.
  • Vertex Pharmaceuticals Incorporated
  • Vera Therapeutics, Inc.
  • Omeros Corporation
  • Alnylam Pharmaceuticals, Inc.
  • Others

GLOBAL RARE KIDNEY DISEASES MARKET, BY DISEASE INDICATION- MARKET ANALYSIS, 2020 - 2033

  • C3 Glomerulonephritis (C3GN)
  • Atypical Hemolytic Uremic Syndrome (aHUS)
  • Fabry Disease
  • Immunoglobulin A (IgA) Nephropathy
  • Focal Segmental Glomerulosclerosis (FSGS)
  • Lupus Nephritis
  • Membranous Nephropathy
  • Others

GLOBAL RARE KIDNEY DISEASES MARKET, BY MOLECULE TYPE- MARKET ANALYSIS, 2020 - 2033

  • Biologics
  • Small Molecules

GLOBAL RARE KIDNEY DISEASES MARKET, BY BIOLOGICS TYPE- MARKET ANALYSIS, 2020 - 2033

  • Proteins
  • Monoclonal Antibodies

GLOBAL RARE KIDNEY DISEASES MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033

  • Intravenous
  • Oral
  • Others

GLOBAL RARE KIDNEY DISEASES MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2020 - 2033

  • Combination Therapy
  • Monotherapy

GLOBAL RARE KIDNEY DISEASES MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Taiwan
  • Vietnam
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Iran
  • Qatar
  • Rest of MEA

Table of Contents

1. Rare Kidney Diseases Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Rare Kidney Diseases Market Snippet by Disease Indication
    • 2.1.2. Rare Kidney Diseases Market Snippet by Molecule Type
    • 2.1.3. Rare Kidney Diseases Market Snippet by Biologics Type
    • 2.1.4. Rare Kidney Diseases Market Snippet by Route of Administration
    • 2.1.5. Rare Kidney Diseases Market Snippet by Therapy Type
    • 2.1.6. Rare Kidney Diseases Market Snippet by Country
    • 2.1.7. Rare Kidney Diseases Market Snippet by Region
  • 2.2. Competitive Insights

3. Rare Kidney Diseases Key Market Trends

  • 3.1. Rare Kidney Diseases Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Rare Kidney Diseases Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Rare Kidney Diseases Market Opportunities
  • 3.4. Rare Kidney Diseases Market Future Trends

4. Rare Kidney Diseases Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Rare Kidney Diseases Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Rare Kidney Diseases Market Landscape

  • 6.1. Rare Kidney Diseases Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Rare Kidney Diseases Market - By Disease Indication

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Disease Indication, 2025 & 2033 (%)
    • 7.1.2. C3 Glomerulonephritis (C3GN)
    • 7.1.3. Atypical Hemolytic Uremic Syndrome (aHUS)
    • 7.1.4. Fabry Disease
    • 7.1.5. Immunoglobulin A (IgA) Nephropathy
    • 7.1.6. Focal Segmental Glomerulosclerosis (FSGS)
    • 7.1.7. Lupus Nephritis
    • 7.1.8. Membranous Nephropathy
    • 7.1.9. Others

8. Rare Kidney Diseases Market - By Molecule Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Molecule Type, 2025 & 2033 (%)
    • 8.1.2. Biologics
    • 8.1.3. Small Molecules

9. Rare Kidney Diseases Market - By Biologics Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Biologics Type, 2025 & 2033 (%)
    • 9.1.2. Proteins
    • 9.1.3. Monoclonal Antibodies

10. Rare Kidney Diseases Market - By Route of Administration

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
    • 10.1.2. Intravenous
    • 10.1.3. Oral
    • 10.1.4. Others

11. Rare Kidney Diseases Market - By Therapy Type

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Therapy Type, 2025 & 2033 (%)
    • 11.1.2. Combination Therapy
    • 11.1.3. Monotherapy

12. Rare Kidney Diseases Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Rare Kidney Diseases Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Rare Kidney Diseases Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.3.18. Denmark
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.18.3. Denmark Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.3.18.4. Denmark Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.3.18.5. Denmark Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.3.18.6. Denmark Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.18.7. Denmark Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.3.19. Rest of Europe
      • 12.3.19.1. Overview
      • 12.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.3.19.3. Rest of the Europe Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.3.19.4. Rest of the Europe Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.3.19.5. Rest of the Europe Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.3.19.6. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.3.19.7. Rest of the Europe Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Rare Kidney Diseases Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.4.17. Taiwan
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.17.3. Taiwan Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.4.17.4. Taiwan Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.4.17.5. Taiwan Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.4.17.6. Taiwan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.17.7. Taiwan Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.4.18. Vietnam
      • 12.4.18.1. Overview
      • 12.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.18.3. Vietnam Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.4.18.4. Vietnam Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.4.18.5. Vietnam Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.4.18.6. Vietnam Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.18.7. Vietnam Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.4.19. Rest of APAC
      • 12.4.19.1. Overview
      • 12.4.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.4.19.3. Rest of APAC Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.4.19.4. Rest of APAC Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.4.19.5. Rest of APAC Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.4.19.6. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.4.19.7. Rest of APAC Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Rare Kidney Diseases Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Rare Kidney Diseases Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.6.15. Iran
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.15.3. Iran Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.6.15.4. Iran Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.6.15.5. Iran Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.6.15.6. Iran Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.15.7. Iran Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.6.16. Qatar
      • 12.6.16.1. Overview
      • 12.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.16.3. Qatar Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.6.16.4. Qatar Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.6.16.5. Qatar Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.6.16.6. Qatar Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.16.7. Qatar Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.6.17. Rest of MEA
      • 12.6.17.1. Overview
      • 12.6.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 12.6.17.3. Rest of MEA Market Size and Forecast, By Disease Indication, 2020 - 2033 (US$ Million)
      • 12.6.17.4. Rest of MEA Market Size and Forecast, By Molecule Type, 2020 - 2033 (US$ Million)
      • 12.6.17.5. Rest of MEA Market Size and Forecast, By Biologics Type, 2020 - 2033 (US$ Million)
      • 12.6.17.6. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 12.6.17.7. Rest of MEA Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)

13. Key Vendor Analysis- Rare Kidney Diseases Industry

  • 13.1. Competitive Benchmarking
    • 13.1.1. Competitive Dashboard
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. Merck & Co., Inc.
    • 13.2.2. Sanofi S.A.
    • 13.2.3. AstraZeneca plc / AstraZeneca Rare Disease
    • 13.2.4. Novartis AG
    • 13.2.5. Otsuka Pharmaceutical Co., Ltd.
    • 13.2.6. Amgen Inc.
    • 13.2.7. Protalix Biotherapeutics Inc.
    • 13.2.8. Recordati S.p.A.
    • 13.2.9. Amicus Therapeutics, Inc.
    • 13.2.10. Travere Therapeutics, Inc.
    • 13.2.11. FibroGen, Inc.
    • 13.2.12. Akebia Therapeutics, Inc.
    • 13.2.13. Aurinia Pharmaceuticals Inc.
    • 13.2.14. Asahi Kasei Corporation (Calliditas Therapeutics)
    • 13.2.15. Apellis Pharmaceuticals, Inc.
    • 13.2.16. Vertex Pharmaceuticals Incorporated
    • 13.2.17. Vera Therapeutics, Inc.
    • 13.2.18. Omeros Corporation
    • 13.2.19. Alnylam Pharmaceuticals, Inc.
    • 13.2.20. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us